zhpsЖурнал прикладной спектроскопииZhurnal Prikladnoii Spektroskopii0514-7506B. I. Stepanov Institute of Physics of the National Academy of Scienceszhps-939Research ArticleСтатьиИсследованиe принудительной деградации натеглинида методом спектрофотометрии на основе первой производной и теории функционала плотностиForced degradation studies of nateglinide by the first-order derivative spectrophotometric method and the density functional theory of the nateglinide moleculeKarasakalA.KarasakalA.

Текирдаг

Science and Letters Faculty, Department of Chemistry,

Tekirdag

akarasakal@nku.edu.trGürkanY. Y.GürkanY. Y.

Текирдаг

Science and Letters Faculty, Department of Chemistry,

Tekirdag

Университет Намик КемальNamik Kemal University202128112021886914919Copyright © Karasakal A., Gürkan Y.Y., 20212021Karasakal A., Gürkan Y.Y.Karasakal A., Gürkan Y.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://zhps.ejournal.by/jour/article/view/939

Оценена стабильность натеглинида (NAT) — перорального антигипергликемического препарата для лечения инсулинозависимого сахарного диабета — в различных условиях принудительной деградации (кислотной, щелочной) и предсказан механизм деградации молекулы NAT в газе и водной среде. Для идентификации NAT и продуктов его распада использован метод спектрофотометрии на основе первой производной. Обнаружена устойчивость NAT к кислой среде, но не к щелочной. Проанализирован вероятный путь взаимодействия молекулы NAT с радикалами ОН. Оптимизированная геометрия рассчитана с помощью программы Gauss View 5. Для данной геометрии с помощью программы Gaussian 09 определено самое низкое энергетическое состояние. Для определения промежуточных звеньев фотокаталитического разложения с помощью теории функционала плотности рассчитаны оптимизированная геометрия молекулы и энергия активации реакции. Найдено наиболее стабильное с термодинамической точки зрения состояние продуктов распада для газовой фазы и водной среды. Предсказанный механизм подтвержден сравнением с экспериментальными результатами для простых структур. 

Nateglinide (NAT) is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus. We evaluated the NAT stability under various forced degradation tests (acidic, basic) and predicted the degradation mechanism of the NAT molecule in the gaseous phase and aqueous media. A firstorder derivative spectrophotometric method was used for the identification of NAT and the products of its degradation. NAT appeared to be stable in acidic but not in basic media. A probable reaction path of the NAT molecule with OH radicals was analyzed. The optimized geometry was calculated with Gauss View 5. Subsequently, the lowest energy status was determined through geometric optimization using Gaussian 09 software. Aiming to determine the intermediates in the photocatalytic degradation mechanism, the geometric optimization of the molecule was realized using the density functional theory method. The activation energy for the probable reaction path was calculated, and their most stable state from the thermodynamic perspective determined for the gaseous phase and aqueous media. The predicted mechanism was confirmed by comparison with the experimental results on simple structures reported in the literature. 

натеглинидпринудительная деградациятеория функционала плотностиметод спектрофотометрии на основе первой производнойnateglinideforced degradation studydensity functional theoryfirst order derivative spectrophotometric methodThis work was supported by the Research Fund of the University of Namik Kemal (Project No. NKUBAP.00.GA.19.217).ReferencesThe Merck Index, 13th ed., Nateglinide, Merck, Inc., Whitehouse Station (2001).The Merck Index, 13th ed., Nateglinide, Merck, Inc., Whitehouse Station (2001).C. J. Dunn, D. Faulds, Drugs, 60, 607–617 (2000).C. J. Dunn, D. Faulds, Drugs, 60, 607–617 (2000).WHO, https://www.who.int/health-topics/diabetes, accessed 07.02.2020.WHO, https://www.who.int/health-topics/diabetes, accessed 07.02.2020.A. B. Thomas, S. D. Patil, R. K. Nanda, L. P. Kothapalli, S. S. Bhosle, A. D. Deshpande, Saudi Pharm. J., 19, No. 4, 221–231 (2011).A. B. Thomas, S. D. Patil, R. K. Nanda, L. P. Kothapalli, S. S. Bhosle, A. D. Deshpande, Saudi Pharm. J., 19, No. 4, 221–231 (2011).A. Rastogi, K. Jha Kishore, V. Verma, J. Singh, J. Sagar, Pharma Res., 1, 169 (2009).A. Rastogi, K. Jha Kishore, V. Verma, J. Singh, J. Sagar, Pharma Res., 1, 169 (2009).M. Sireesha, R. S. Chandan, B. M. Gurupadayya, A. Shravya, Pharma Chem., 3, 497–506 (2011).M. Sireesha, R. S. Chandan, B. M. Gurupadayya, A. Shravya, Pharma Chem., 3, 497–506 (2011).D. E. Han, Y. Zheng, N. Li, D. Zhao, G. Zhang, H. Yan, L. Zhang, W. Sun, Y. N. Wu, Y. Lu, X. Chen, Chromatographia, 71, 299–304 (2010).D. E. Han, Y. Zheng, N. Li, D. Zhao, G. Zhang, H. Yan, L. Zhang, W. Sun, Y. N. Wu, Y. Lu, X. Chen, Chromatographia, 71, 299–304 (2010).C. B. Ojeda, F. S. Rojas, Anal. Chim. Acta, 518, 1–24 (2004).C. B. Ojeda, F. S. Rojas, Anal. Chim. Acta, 518, 1–24 (2004).F. S. Rojas, C. B. Ojeda, J. M. Pavon, Talanta, 35, 753–761 (1988).F. S. Rojas, C. B. Ojeda, J. M. Pavon, Talanta, 35, 753–761 (1988).J. Karpińska, Talanta, 64, 801–822 (2004).J. Karpińska, Talanta, 64, 801–822 (2004).A. A. Shirkhedkar, H. C. Bhirud, J. S. Surana, Pak. J. Pharm. Sci., 22, 27–29 (2009).A. A. Shirkhedkar, H. C. Bhirud, J. S. Surana, Pak. J. Pharm. Sci., 22, 27–29 (2009).C. Jenee, S. Purvi, P. Margi, P. Kalpana, G. Tejal, J. Taibah Univ. Sci., 11, 729–740 (2017).C. Jenee, S. Purvi, P. Margi, P. Kalpana, G. Tejal, J. Taibah Univ. Sci., 11, 729–740 (2017).A. S. Dimal, J. S. Dixita, N. D. Chirag, K. C. Usman, K. B. Kashyap, Arab. J. Chem., 10, 105–108 (2017).A. S. Dimal, J. S. Dixita, N. D. Chirag, K. C. Usman, K. B. Kashyap, Arab. J. Chem., 10, 105–108 (2017).International Conference on Harmonization. ICH. Validation of analytical procedures: text and methodology Q2 R1 (2005).International Conference on Harmonization. ICH. Validation of analytical procedures: text and methodology Q2 R1 (2005).International Conference on Harmonization, ICH. Stability testing of new drug substances and products Q1A R2 (2003).International Conference on Harmonization, ICH. Stability testing of new drug substances and products Q1A R2 (2003).V. G. Buxton, L. C. Greenstock, P. W. Helman, B. A. Ross, J. Phys. Chem., 17, 513–886 (1988).V. G. Buxton, L. C. Greenstock, P. W. Helman, B. A. Ross, J. Phys. Chem., 17, 513–886 (1988).M. Anbar, P. Neta, Int. J. Appl. Radiat. Isot., 18, 495–523 (1965).M. Anbar, P. Neta, Int. J. Appl. Radiat. Isot., 18, 495–523 (1965).B. Halliwell, M. Grootveld, J. M. C. Gutteridge, Methods Biochem. Anal., 33, 59–90 (2006).B. Halliwell, M. Grootveld, J. M. C. Gutteridge, Methods Biochem. Anal., 33, 59–90 (2006).A. Hatipoglu, D. Vione, Y. Yalcin, C. Minero, Z. Cinar, J. Photochem. Photobiol. A: Chem., 215, 59–68 (2010).A. Hatipoglu, D. Vione, Y. Yalcin, C. Minero, Z. Cinar, J. Photochem. Photobiol. A: Chem., 215, 59–68 (2010).P. W. Atkins, Physical Chemistry, 6th ed., Oxford University Press, New York (1998).P. W. Atkins, Physical Chemistry, 6th ed., Oxford University Press, New York (1998).K. K. Mierzejewska, J. Trylska, J. Sadlej, J. Mol. Model., 18, 2727–2740 (2012).K. K. Mierzejewska, J. Trylska, J. Sadlej, J. Mol. Model., 18, 2727–2740 (2012).Gaussian 09, Revision B.04, Gaussian, Inc., Pittsburgh, PA (2009).Gaussian 09, Revision B.04, Gaussian, Inc., Pittsburgh, PA (2009).D. B. Pathare, A. S. Jadhav, M. S. Shingare, Drug Dev. Ind. Pharm., 33, No. 5, 551–557 (2007).D. B. Pathare, A. S. Jadhav, M. S. Shingare, Drug Dev. Ind. Pharm., 33, No. 5, 551–557 (2007).Asha Byju Thomas, Shrikrushn, Digambar Patil, Rabindra Kumar Nanda, Lata Prasad Kothapalli, Shital Shridhar Bhosle, Avinash Devidas Deshpande, Saudi Pharm. J., 19, No. 4, 221–231 (2011).Asha Byju Thomas, Shrikrushn, Digambar Patil, Rabindra Kumar Nanda, Lata Prasad Kothapalli, Shital Shridhar Bhosle, Avinash Devidas Deshpande, Saudi Pharm. J., 19, No. 4, 221–231 (2011).K. Basavaiah, N. Rajendraprasad, Austin J. Anal. Pharm. Chem., 5, No. 1, 1096 (2018).K. Basavaiah, N. Rajendraprasad, Austin J. Anal. Pharm. Chem., 5, No. 1, 1096 (2018).A. Karasakal, E. Ozdemir, J. Res. Pharm., 23, No. 3, 457–464 (2019).A. Karasakal, E. Ozdemir, J. Res. Pharm., 23, No. 3, 457–464 (2019).

The authors declare that there are no conflicts of interest present.